Latest news with #Allopurinol
Business Standard
23-05-2025
- Business
- Business Standard
Indoco Remedies gains after receiving USFDA nod for Allopurinol drug
Indoco Remedies rose 1.28% to Rs 245.80 after the company announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Allopurinol tablets. Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. The drug is the generic equivalent of the reference listed drug (RLD), Zyloprim, marketed by Casper Pharma LLC. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The pharmaceutical company reported a standalone net loss of Rs 10.23 crore in Q3 FY25 as against a net profit of Rs 20.01 crore posted in Q3 FY24. Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24.
Business Upturn
23-05-2025
- Business
- Business Upturn
Indoco Remedies receives USFDA approval for Generic Allopurinol Tablets USP 200 mg
By Aman Shukla Published on May 23, 2025, 11:20 IST Indoco Remedies Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP 200 mg. The approved product is a generic version of Zyloprim® 200 mg, originally marketed by Casper Pharma LLC. Allopurinol is commonly prescribed to manage high levels of uric acid in the blood, a condition known as hyperuricemia. It is also used to control uric acid levels in patients undergoing cancer treatment or those with kidney stones, where elevated uric acid can cause further complications. The approved product will be manufactured at Indoco Remedies' production facility located at L-14, Verna Industrial Area, Verna, Goa – 403722, India. Aditi Panandikar, Managing Director, commented, 'Besides reflecting the capability of Indoco Remedies to deliver products of high-quality standards, this development also provides impetus to our growth aspirations in an important market such as the US.' This approval allows Indoco Remedies to market Allopurinol Tablets USP 200 mg in the U.S. market, providing a therapeutic alternative for patients and contributing to the availability of cost-effective generic medications. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
